The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2020 | Venetoclax for AML
Daniel Pollyea, MD, MS, of the University of Colorado, Denver, CO, outlines the use of venetoclax, a BCL-2 inhibitor, in acute myeloid leukemia (AML) and caveats associated with its use, including moving this treatment beyond its approved indication in unfit, relapsed/refractory AML. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
